Profound Medical(NASDAQ) PROF

Profound Medical Corp. helps doctors treat diseased tissue without surgery. It uses imaging and ultrasound to destroy unhealthy cells inside the body. Patients recover quickly because these procedures require no incisions or radiation.

Tools for Targeted Treatment

• TULSA-PRO: Combines real-time magnetic resonance imaging with robotically driven ultrasound to destroy prostate tissue from inside the urethra.
• Sonalleve: Therapeutic platform designed for noninvasive treatment of uterine fibroids and relief from bone metastasis pain.
• One-Time-Use Devices: Disposable components required for each procedure that generate recurring revenue for the company.
• Capital Equipment: Hardware systems sold or leased to hospitals for use with their existing imaging infrastructure.

Global Expansion and Financing

• Raised $40.8 million in net proceeds through a public offering and private placement in December 2025.
• Amended a credit agreement with Canadian Imperial Bank of Commerce in March 2025 for a revolving line.
• Finished patient enrollment for the CAPTAIN clinical trial in early 2026.
• Reduced research and development spending on clinical trials following the completion of trial enrollment.

Smart Imaging Integration

Profound Medical uses existing hospital magnetic resonance imaging scanners to perform precise, pixel-by-pixel tissue destruction. This approach eliminates the need for surgery while protecting vital urinary and sexual functions for patients.

Recent Financial Performance

• Revenue reached $7.8 million for the six months ended June 30, 2026, up 62% year over year.
• Net loss was $16.6 million for the first half of 2026, down 37% year over year.
• Gross profit for the quarter ended June 30, 2026, rose 20% year over year to $1.9 million.
• Cash balances totaled $38.3 million as of June 30, 2026, compared to $59.7 million at the end of 2025.
• Market capitalization reached $323.0 million in Q1 2026, up 31.0% year over year.

The Company's Evolution

Profound Medical has transitioned from a technology developer to a commercial provider of incision-free therapies in global markets. The company uses a hybrid sales model to generate immediate equipment revenue and long-term income from disposables.